Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.
Ontaneda D, Tallantyre EC, Raza PC, Planchon SM, Nakamura K, Miller D, Hersh C, Craner M, Bale C, Chaudhry B, Gunzler DD, Love TE, Gerry S, Coles A, Cohen JA, Evangelou N. Ontaneda D, et al. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. Epub 2020 Apr 19. Contemp Clin Trials. 2020. PMID: 32320842
Comparative effectiveness studies in multiple sclerosis.
Hersh CM, Hua LH. Hersh CM, et al. Neurodegener Dis Manag. 2020 Jun;10(3):113-118. doi: 10.2217/nmt-2020-0015. Epub 2020 Jun 5. Neurodegener Dis Manag. 2020. PMID: 32501735 No abstract available.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS).
Mowry EM, Bermel RA, Williams JR, Benzinger TLS, de Moor C, Fisher E, Hersh CM, Hyland MH, Izbudak I, Jones SE, Kieseier BC, Kitzler HH, Krupp L, Lui YW, Montalban X, Naismith RT, Nicholas JA, Pellegrini F, Rovira A, Schulze M, Tackenberg B, Tintore M, Tivarus ME, Ziemssen T, Rudick RA. Mowry EM, et al. Among authors: hersh cm. Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. eCollection 2020. Front Neurol. 2020. PMID: 32849170 Free PMC article.
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
Hersh CM, Kieseier B, de Moor C, Miller DM, Campagnolo D, Williams JR, Fitzgerald KC, Xiong K, McGinley MP, Hyland M, Rudick RA, Ziemssen T, Koulinska I. Hersh CM, et al. Mult Scler J Exp Transl Clin. 2021 Apr 15;7(2):20552173211004634. doi: 10.1177/20552173211004634. eCollection 2021 Apr-Jun. Mult Scler J Exp Transl Clin. 2021. PMID: 33948221 Free PMC article.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
Ziemssen T, Giovannoni G, Alvarez E, Bhan V, Hersh C, Hoffmann O, Oreja-Guevara C, Robles-Cedeño RR, Trojano M, Vermersch P, Dobay P, Khwaja M, Stadler B, Rauser B, Hach T, Piani-Meier D, Burton J. Ziemssen T, et al. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. J Med Internet Res. 2021. PMID: 34612826 Free PMC article.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Cohen JA, et al. Among authors: hersh cm. Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994577 Free PMC article.
Updates and advances in multiple sclerosis neurotherapeutics.
Amin M, Hersh CM. Amin M, et al. Among authors: hersh cm. Neurodegener Dis Manag. 2023 Feb;13(1):47-70. doi: 10.2217/nmt-2021-0058. Epub 2022 Oct 31. Neurodegener Dis Manag. 2023. PMID: 36314777 Free PMC article. Review.
Associations of sNfL with clinico-radiological measures in a large MS population.
Sotirchos ES, Fitzgerald KC, Singh CM, Smith MD, Reyes-Mantilla M, Hersh CM, Hyland MH, Canissario R, Simmons SB, Arrambide G, Montalban X, Comabella M, Naismith RT, Qiao M, Krupp LB, Nicholas JA, Akgün K, Ziemssen T, Rudick R, Fisher E, Bermel RA, Mowry EM, Calabresi PA. Sotirchos ES, et al. Among authors: hersh cm. Ann Clin Transl Neurol. 2023 Jan;10(1):84-97. doi: 10.1002/acn3.51704. Epub 2022 Nov 25. Ann Clin Transl Neurol. 2023. PMID: 36427295 Free PMC article.
42 results